LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
23.2.2021 01:33:00 EET | Business Wire | Press release
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.
“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”
Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”
According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
LG Chem Life Sciences Innovation Center: innovation.lgchem.com
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005934/en/
Contact information
Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
What Europeans Really Want From Their Next Smartphone13.10.2026 14:01:00 EEST | Press release
If you’ve ever bought running shoes for the runner you hoped to become or luggage for a yet to be planned trip, you’re not alone. New research from Samsung reveals that Europeans1 take a similar aspirational approach when choosing a smartphone. More than two thirds (66%2) of Europeans surveyed1 chose their current smartphone with at least one interest they wanted to pursue in mind, with interests ranging from entertainment and side hustles to gaming, travel and content creation. In fact, almost half (46%3) consider their ambitions when making technology choices, including 24% who say their choices are primarily shaped by the life they aspire to lead. Additionally, almost a third (28%) reported that they chose their current smartphone to better reflect their personal style. Having a variety of options to choose from is important when considering the wide range of aspirations and focuses of European consumers. Big ambitions, everyday needs Europeans1 may be choosing smartphones with futu
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules13.10.2026 14:00:00 EEST | Press release
Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform. Enodia’s proprietary platform enables selective Sec61 Translocon modulation, a novel approach to inhibit disease-driving proteins at the point of synthesis before pathological effects occur, while preserving essential physiological functions. Enodia has built a broad and well-characterized chemical space spanning multiple Sec61 inhibitor families, supported by extensive biological datasets, including proteomics, cryo-EM and tailored cell-line libraries that enable rational small-molecule design powered by machine learning. “Enodia has built a broad platform t
TradingHub Appoints Phil Snow as Chairman13.10.2026 12:00:00 EEST | Press release
TradingHub today announced the appointment of Phil Snow as Chairman, further strengthening the company's leadership as it continues to expand its global presence and invest in innovation across trade surveillance. Phil brings three decades of experience in financial technology, data and analytics, built at FactSet, where he served as Chief Executive Officer from 2015 to 2025. Under his leadership, FactSet more than doubled its revenue, joined the S&P 500 and expanded its products and global presence. The appointment follows TradingHub's recent investment from Nordic Capital and reflects the shared ambition to support the company's next phase of growth while building on the strong foundations established by its leadership team. "Phil is an outstanding appointment for TradingHub, and I am delighted to welcome him as Chairman," said Mike Coats, Chief Executive Officer of TradingHub. "He spent a decade running a global financial data company that serves many of the same institutions we do,
Bregal Milestone Backs Asolvi to Build AI-First Field Service Software for Compliance-Critical Industries13.10.2026 11:00:00 EEST | Press release
Bregal Milestone, a leading European growth private equity firm specialising in software, today announced a majority investment in Asolvi, a provider of field service management (FSM) software for compliance-critical and asset-intensive industries. Bregal Milestone is acquiring its stake from Volpi Capital and Viking Growth. CEO Nick Barnett and the management team are reinvesting alongside Bregal Milestone. Founded in 1991 and headquartered in Trondheim, Norway, Asolvi serves more than 2,000 customers across the UK, DACH, the Nordics, Spain and Latin America. For fire and security installers and utility contractors, Asolvi’s software is the operating system of the business. It schedules engineers, manages maintenance contracts, records inspections, and produces evidence that regulators, insurers and building owners require. Because Asolvi sits at the centre of these workflows, it captures structured data on assets, inspections, parts, and outcomes as jobs are completed. This puts Asol
YouHodler Italy Authorised by CONSOB as a Crypto-Asset Service Provider Under MiCA13.10.2026 10:00:00 EEST | Press release
YouHodler Italy S.r.l., announces that CONSOB, after hearing the Bank of Italy, has authorised it as a crypto-asset service provider (CASP) under Regulation (EU) 2023/1114 (MiCA) and Legislative Decree 129/2024, by resolution no. 24156 of 8 October 2026. The authorisation covers five services: custody and administration of crypto-assets on behalf of clients; exchange of crypto-assets for funds; exchange of crypto-assets for other crypto-assets; execution of orders on behalf of clients; and transfer services for crypto-assets on behalf of clients. With the authorisation, YouHodler Italy serves clients in Italy as a supervised firm under MiCA's client protections: segregation of client crypto-assets, governance and security requirements, pre-contractual information and complaints handling. The company plans to extend its services to all 27 EU Member States through the procedure set out in the Regulation. "The CONSOB authorisation is the result of long and rigorous work with the authoriti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom